Teneligliptin Hydrochloride API is a salt form of Teneligliptin, a synthetic small-molecule dipeptidyl peptidase-4 (DPP-4) inhibitor used in pharmaceutical formulations for the management of type 2 diabetes mellitus.
Teneligliptin inhibits DPP-4, an enzyme responsible for the degradation of incretin hormones. By inhibiting DPP-4 activity, Teneligliptin helps enhance incretin-mediated glucose-dependent insulin secretion and contributes to improved glycemic control.
PubChem identifies Teneligliptin Hydrochloride with the molecular formula C₂₂H₃₁ClN₆OS and molecular weight 463.0 g/mol. The parent Teneligliptin has CAS 760937-92-6.
Swapnroop provides Teneligliptin Hydrochloride API for pharmaceutical formulation, development, analytical research and manufacturing applications.
Teneligliptin is a long-acting, orally active DPP-4 inhibitor. Its inhibition of DPP-4 increases the availability of incretin hormones such as GLP-1 and GIP, supporting glucose-dependent insulin secretion.
Teneligliptin is primarily associated with pharmaceutical treatment of type 2 diabetes mellitus.
Teneligliptin Hydrochloride is the hydrochloride salt of the active molecule Teneligliptin.
Product Name: Teneligliptin Hydrochloride
CAS Number: Not consistently established in authoritative public databases for the simple hydrochloride form
Molecular Formula: C₂₂H₃₁ClN₆OS
Molecular Weight: 463.0 g/mol
Parent API: Teneligliptin
Parent CAS Number: 760937-92-6
API Type: Small-Molecule API
Therapeutic Category: Antidiabetic
Drug Class: DPP-4 Inhibitor
Pharmaceutical Application: Type 2 Diabetes Mellitus
PubChem specifically records the hydrochloride molecular formula as C₂₂H₃₁ClN₆OS and molecular weight as 463.0 g/mol.
Teneligliptin Hydrochloride is associated with pharmaceutical formulations for:
Teneligliptin Hydrochloride API should be evaluated using validated analytical procedures appropriate to the exact salt form and manufacturing specification.
Typical quality-control parameters may include:
Important: The Indian Pharmacopoeia Commission monograph available publicly is for Teneligliptin Hydrobromide Hydrate, not Teneligliptin Hydrochloride. Therefore, the numerical IPC limits for the hydrobromide hydrate should not be copied onto a Teneligliptin Hydrochloride product page.
Swapnroop provides Teneligliptin Hydrochloride API for pharmaceutical formulation, development and manufacturing requirements.
Our quality-focused approach includes controlled manufacturing, analytical characterization and pharmaceutical documentation designed to support pharmaceutical customers.
Teneligliptin Hydrochloride should be packaged in suitable pharmaceutical-grade, well-closed containers that protect the API from moisture, contamination and environmental exposure.
Storage conditions should follow validated stability data and the applicable product specification.
Depending on product grade and customer requirements, documentation may include:
| Parameter | Specification |
|---|---|
| Appearance | white to off-white crystalline powder |
| Identification | IR & HPLC compliant |
| Assay (HPLC) | 98.0% – 102.0% |